HSP90AB1 and colon carcinoma: We showed using a cell-based reporter assay that IDH3 activity is reduced by >50% following HSP90 inhibition in HT29 cells, as well as in two other cell lines—HCT116 colon carcinoma, and BT474 breast ductal carcinoma (Fig. 6B).